A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.

ABSTRACT: Adherence to medication regimens is a major barrier to effective treatment in many disease areas, notably in dementia which causes cognitive impairment that reduces patients' awareness of non-adherence and their ability to manage medication. The development of oral dosage forms that can be infrequently dosed, and therefore improve adherence rate and facilitate direct observed therapy, has been a goal for decades. We describe the first demonstration of an oral formulation that achieves >7-day gastric retention and sustained pharmacokinetics in the challenging dog model. Gastric retention requires physical resistance of the dosage form to gastric emptying forces, which are known to be stronger in dogs than in humans, making successful gastric retention in dogs a stringent test for predicting

SUBMITTER: Kanasty R 

PROVIDER: S-EPMC6587581 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature